Black Diamond Therapeutics Inc (BDTX) Stock Forecast & Price Target
Black Diamond Therapeutics Inc · NASDAQ
$1.73-0.03 (-1.70%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Black Diamond Therapeutics Inc, 6 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $8.00 to $14.00, a moderate spread. The average target of $9.83 sits 468% above the current $1.73. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.06 next quarter toward $-1.16 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Moderate Buy
Strong Buy00%
Buy686%
Hold114%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Black Diamond Therapeutics Inc.
As of Jul, 6 of 7 firms rate BDTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BDTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.26 – $0.60 · 6 analysts · -60% YoY
Next period, 6 analysts expect Black Diamond Therapeutics Inc to earn $-0.06 a share (range $-0.26 – $0.60), versus $-0.15 a year earlier. Full-year consensus is $-0.63, growing to $-1.16 the year after.
REVENUE · NEXT QUARTER
$5.6M
Range $0 – $50.0M · 6 analysts
Revenue is expected to reach $5.6M (range $0 – $50.0M). Full-year consensus is $5.6M, rising to $0 next year.
Top analysts covering Black Diamond Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BDTX.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$10.00+478.0% to target
Overall win rate
38%
+ Follow
#2
Joseph Catanzaro
Piper Sandler · Rank #219
Buy
$15.00+767.1% to target
Overall win rate
41%
+ Follow
#3
Robert Driscoll
Wedbush · Rank #313
Buy
$14.00+709.2% to target
Overall win rate
30%
+ Follow
#4
Kelsey Goodwin
Piper Sandler
Buy
$8.00+362.4% to target
Coverage
—
+ Follow
#5
LP
Laura Prendergast
Stifel
Buy
$8.00+362.4% to target
Coverage
—
+ Follow
BDTX stock forecast FAQ
What is BDTX's average 12-month price target?+
The 5 analysts with a live target average $9.83 for Black Diamond Therapeutics Inc over the next 12 months, ranging from a $14.00 high to a $8.00 low.
Is BDTX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 7 analyst ratings, 6 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BDTX?+
The Street-high target is $14.00 (Wedbush), and the Street-low is $8.00 (Piper Sandler). The average of all 5 active targets is $9.83.
How many Wall Street analysts cover BDTX?+
7 analysts have an active rating on Black Diamond Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering BDTX?+
Among analysts who currently cover BDTX, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #195). Their current call is Buy with a $10.00 target.
What is Black Diamond Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.26 – $0.60) across 6 analysts. Full-year EPS is projected at $-0.63, rising to $-1.16 the following year.
How much revenue is Black Diamond Therapeutics Inc expected to report next quarter?+
Consensus revenue is $5.6M (range $0 – $50.0M). Full-year revenue is projected at $5.6M, growing to $0 next year.
Have analysts been upgrading or downgrading BDTX lately?+
As of Jul, 6 of 7 firms rate BDTX a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BDTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
